This page cannot tell you whether Valeda is right for you. Candidacy depends on your vision, the appearance of your macula, and other findings from a comprehensive exam and imaging. Your doctor decides.

FDA labeling, in brief

According to the FDA indications, Valeda is intended for people who have:

• best-corrected visual acuity from 20/32 through 20/70, and
• dry AMD with at least three medium drusen, or large drusen, or non-central geographic atrophy, and
• no neovascular (wet) maculopathy and no center-involving geographic atrophy.

Those criteria are labeling, not a self-test. Measurements such as “medium” versus “large” drusen are made by a clinician, often with imaging, not from a symptom checklist.

Other limits in the FDA summary

The decision summary lists contraindications and precautions, including:

• known photosensitivity to yellow, red, or near-infrared light, or a history of light-activated central nervous system disorders (for example, epilepsy or migraine)
• not treating within 30 days of photosensitizing agents without a physician’s advice
• safety and effectiveness not established in people under 50, pregnant or nursing people, and several other groups excluded from the study (including current or prior neovascular maculopathy, center-involving GA within the central 1 mm, and media opacities that interfere with vision or imaging)
• no non-white subjects received treatment in the study, so clinical performance in non-white patients is unknown
• a subgroup analysis of patients classified as early AMD (Beckman classification) showed little between-arm difference; a practitioner should consider that profile before treating people with that classification
• treatment benefit may not persist significantly after treatment is stopped
• people whose fellow eye has neovascular AMD should be monitored closely (the summary reports conversion numbers in a small subgroup)

If Valeda is not a fit, your doctors can still help with monitoring, lifestyle and supplement conversations, and the right path for wet AMD or advanced disease when needed.

Book an exam

You can choose your office and book an exam online, or call Hazleton Eye Specialists at 570-453-2020.

Sources

• U.S. Food and Drug Administration. DEN230083 decision summary.

Medical disclaimer. This page is for general education only. It is not medical advice and does not replace an examination or a conversation with your own doctors. Do not start, stop, or change any medicine or treatment without talking to the clinician who cares for you. If you notice new wavy lines, a sudden blur, or a blank spot in your central vision, seek same-day care from an eye doctor or an emergency department.